Abstract
Exoproteinase production was demonstrated in 64 clinical isolates ofS. marcescens. A significant relationship was found between the site of origin (autopsy material, hemocultures, various other sources), proteinase activity, and LD50 of the analyzed isolates. The number of exoproteinases varied during a 14-h incubation in batch cultures; the most frequently found was a 57.5-kDa proteinase which was observed in all analyzed strains. The exoproteinase production was shown to be related to strain virulence.
Similar content being viewed by others
References
Abbot S.:Klebsiella, Enterobacter, Citrobacter, andSerratia, pp. 475–482 in P.R. Murray, E.J. Baron, M.A. Pfaller, F.C. Tenover, R.H. Yolken (Eds):Manual of Clinical Microbiology. ASM Press, Washington (DC) 1999.
Aucken H.M., Pitt T.L.: Antibiotic resistance and putative virulence factors ofSerratia marcescens with respect to O and K serotypes.J.Med.Microbiol.47, 1195–1113 (1998).
Bar-Ness R., Rosenberg M.: Putative role of a 70-kDa outer-surface protein in promoting cell-surface hydrophobicity ofSerratia marcescens RZ.J.Gen.Microbiol.135, 2277–2281 (1989).
Bogyiová E., Siegfried L., Kmeťová M., Šándorčínová Z., Liptáková A., Biroš E.: Occurrence and genetic association of selected virulence factors in clinicalEscherichia coli isolates.Folia Microbiol.47, 73–77 (2002).
Bollman R., Halle E., Sokolowska-Kohler W., Grauel E.L., Bucholz P., Klare I., Tshapé H., Witte W.: Nosocomial infections due toSerratia marcescens, clinical findings, antibiotic susceptibility patterns and fine typing.Infection17, 294–300 (1989).
Bromke B.J., Venuti E.: A basal-defined medium for the study of proteolytic activity ofSerratia marcescens.Can.J.Microbiol.45, 88–91 (1999).
Carbonell G.V., Fonseca B.A.L., Figuereido L.T.M., Darini A.L.C., Yanaguita R.M.: Culture conditions affect cytotoxin production bySerratia marcescens.FEMS Immunol.Med.Microbiol.16, 299–307 (1996).
Carbonell G.V., Vidotto M.C.: Virulence factors inSerratia marcescens: cell-bound hemolysin and aerobactin.Braz.J.Med.Biol.Res.25, 1–8 (1992).
Coria-Jiménez R., Ortiz-Torres C.: Aminoglycoside resistance ofSerratia marcescens strains of clinical origin.Epidemiol.Infect.112, 125–131 (1994).
Coria-Jiménez R., Romero-Olvera J., Celis-Cruz C.: Superficial hydrophobicity inSerratia marcescens strains of clinical origin.Res.Microbiol.149, 27–29 (1998).
Dworniczek E., Kuzko K., Mróz E., Wojciech L., Adamski R., Sobieszczańska B., Seniuk A.: Virulence factors andin vitro adherence ofEnterococcus strains to urinary catheters.Folia Microbiol.48, 671–678 (2003).
Farmer J.J.:Enterobacteriaceae: introduction and identification, pp. 442–458 in P.R. Murray, E.J. Baron, M.A. Pfaller, F.C. Tenover, R.H. Yolken (Eds):Manual of Clinical Microbiology, ASM Press, Washington (DC) 1999.
Franiczek R., Sobieszczańska B., Grabowski M., Mowszet K., Pytrus T.: Occurrence of extended-spectrum β-lactamases amongEscherichia coli isolates from hospitalized and healthy children.Folia Microbiol.48, 243–248 (2003).
Hejazi A., Falkiner F.R.:Serratia marcescens.J.Med.Microbiol.46, 903–912 (1997).
Hernández-Delgadillo R., Ruiz-Cruz J.J.: Actividad proteolítica libre deSerratia marcescens II. Cinética de producción y mecanismo de inducción.Rev.Lat-Amer.Microbiol.36, 93–100 (1994).
Hertle R., Hilger M., Weingardt-Kocher S., Walev I.: Cytotoxic action ofSerratia marcescens hemolysin on human epithelial cells.Infect.Immun.67, 817–825 (1999).
Kamata R., Yamamoto T., Matsumoto K., Maeda H.: A serratial protease causes vascular permeability reaction by activation of the Hageman factor-dependent pathway in Guinea pigs.Infect.Immun.48, 747–753 (1985).
Kim N., Kim S.I.: Characterization and primary specificity of an extracellular metalloproteinase fromSerratia marcescens.Can.J.Microbiol.40, 120–126 (1994).
Kunitz M.: Soybean trypsin inhibitor. II. General properties.J.Gen.Physiol.40, 291–310 (1947).
Lockwood B.C., North M.J., Scott K.I., Brenner A.F., Coomles G.H.: The use of a highly sensitive electrophoretic method to compare the proteinases of trichomonads.Mol.Biochem.Parasitol.24, 89–95 (1987).
Lyerly D., Gray L., Kreger A.: Characterization of rabbit corneal damage produced bySerratia keratitis andSerratia protease.Infect.Immun.31, 927–932 (1981).
Lyerly D., Kreger A.: Importance ofSerratia proteases in the pathogenesis of experimentalSerratia marcescens pneumoniae.Infect.Immun.40, 113–119 (1983).
Majtánová L., Majtán V.: Postantibiotic effects of gentamicin and netilmicin onSerratia marcescens: effects on hydrophobicity and motility.Folia Microbiol.45, 45–50 (2000).
Matsumoto K., Maeda H., Takata T., Okamura R.: Purification and characterization of four proteases from clinical isolateSerratia marcescens KUMS 3958.J.Bacteriol.157, 225–232 (1984).
Molla A., Matsumoto A., Oyamada T., Katsuli T., Maeda H.: Degradation of protease inhibitors, immunoglobulins, and other serum proteins bySerratia protease and its toxicity to fibroblasts in culture.Infect.Immun.53, 522–529 (1986).
Molla A., Kagimoto T., Maeda H.: Cleavage of immunoglobulin G (IgG) and IgA around the hinge region by proteases fromSerratia marcescens.Infect.Immun.56, 916–920 (1988).
Montaner B., Navarro S., Pique M., Vilaseca M., Martinell M., Giralt E., Gil J., Perez-Tomas R.: Prodigiosin from the supernatant ofSerratia marcescens induces apoptosis in hematopoietic cancer cell lines.Brit.J.Pharmacol.131, 585–593 (2000).
Poole K., Braun B.: Iron regulation ofSerratta marcescens hemolysin gene expression.Infect Immun.56, 2967–2971 (1998).
Reed L.J., Muench I.I.: A simple method for estimating fifty per cent endpoints.Amer.J.Hyg.27, 493–497 (1938).
Schefler W.C.:Bioestadistica. Fondo Educativo Interamericano, México 1981.
Yu V.L.:Serratia marcescens. Historical perspective and clinical review.New Engl.J.Med.300, 887–893 (1979).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Coria-Jiménez, R., Zárate-Aquino, C. & Ponce-Ponce, O. Proteolytic activity inSerratia marcescens clinical isolates. Folia Microbiol 49, 321–326 (2004). https://doi.org/10.1007/BF02931050
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF02931050